Working… Menu
Trial record 2 of 13 for:    "Adenoma" | "Cabergoline"

Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02288962
Recruitment Status : Recruiting
First Posted : November 13, 2014
Last Update Posted : December 27, 2018
Norwegian University of Science and Technology
Information provided by (Responsible Party):
St. Olavs Hospital

Brief Summary:

Due to lack of hormone overproduction in non-functioning pituitary adenomas (NFPAs), only the symptomatic adenomas or large adenomas with proven growth and risk for symptoms in near future will undergo pituitary surgery. The remaining adenomas are monitored regularly. Operation of these large adenomas will rarely remove all tumour tissue, and there is also a risk of worsening of pituitary function. Often, adenomas with the highest growth potential are operated several times and some also need radiation therapy, providing additional risk for pituitary failure. Unlike some of the hormone-producing adenomas, there is no established pharmacological treatment for NFPAs. However, there are a few non-randomized studies suggesting that treatment with dopamine agonists may slow growth, and also induce tumour shrinkage. At present, cabergoline is the dopamine agonist most widely used in the treatment of pituitary adenomas secreting prolactin.

Aim is to study the effect of medical treatment with cabergoline in non-functioning pituitary adenomas on the change in tumour volume.

Condition or disease Intervention/treatment Phase
Pituitary Neoplasms Adenoma Drug: cabergoline Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial
Actual Study Start Date : November 2014
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : May 2025

Arm Intervention/treatment
Experimental: cabergoline

Target dose for cabergoline is 2 mg/week.The medication is administered in the evening to minimize side effects. If intolerable side effects occur despite this, it may be necessary to treat with a lower dose than 2 mg per week.

Treatment scheme: 0.5 mg x 1 per week the first 2 weeks, then 0.5 mg x 2 per week the next 2 weeks, then 1 + 0.5 mg per week the next 2 weeks, then 1 mg x 2 per week (target dose) for the rest of the study

Drug: cabergoline
Other Names:
  • galastop
  • FCE 21336
  • Cabaser
  • Dostinex
  • Cabaseril
  • cabergoline diphosphate

No Intervention: observation
visits and controls as usual

Primary Outcome Measures :
  1. change in tumour volume during the main study of two years [ Time Frame: 2 years ]
    This includes the percentage and absolute change in tumour volume, but also the number of patients with significant tumour shrinkage or tumour growth (defined by ≥ 10 % or ≥ 2 mm shrinkage/growth in at least one dimension)

Secondary Outcome Measures :
  1. need for surgical and/or radiation treatment [ Time Frame: up till 2 years ]
  2. changed pituitary function [ Time Frame: up till 2 years ]
    measured by analysis of blood tests, basal and stimulation tests

  3. change in tumour's distance to chiasma opticum in mm [ Time Frame: up till 2 years ]
    as measured by analysis of MRI images

  4. development of cardiac valvulopathy [ Time Frame: up till 2 years ]
    as measured by analysis of echo cardiography

  5. impulse control disorder [ Time Frame: up till 2 years ]
    as measured by questionnaire visual files: clinical evaluation by ophthalmologist and perimetry

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A previously untreated non-functioning pituitary macroadenoma (largest diameter ≥ 10 mm) with either demonstrated growth on repeated MRI scans or ≤ 2 mm distance to chiasma opticum, or:
  • a residual non-functioning pituitary adenoma after surgery (largest diameter ≥ 5 mm) that is either extrasellar and/or with documented growth after surgical treatment of a non-functioning pituitary macroadenoma

Exclusion Criteria:

  • Clear indication for surgery at the time of inclusion
  • Previous radiation therapy
  • Pituitary surgery the last 6 months
  • Previous apoplexy/bleeding in the adenoma
  • Pregnancy or lactation
  • Contraindications for cabergoline treatment (Known cardiac valvular disease, known pulmonal, pericardial or retroperitoneal fibrosis, clinical significant liver insufficiency, use of medications that interact with cabergoline
  • unfit to participate due to any other reason

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02288962

Layout table for location contacts
Contact: Stine L Fougner, md phd
Contact: Sven M Carlsen, md phd

Layout table for location information
Department of Endocrinology, Akershus University hospital Recruiting
Oslo, Norway
Department of Endocrinology, St. Olavs Hospital Recruiting
Trondheim, Norway, 7006
Contact: Stine L Fougner, MD PhD   
Sahlgrenska University Hospital Recruiting
Gøteborg, Sweden
Sponsors and Collaborators
St. Olavs Hospital
Norwegian University of Science and Technology
Layout table for investigator information
Principal Investigator: Sven M Carlsen, prof md Norwegian University of Science and Technology

Layout table for additonal information
Responsible Party: St. Olavs Hospital Identifier: NCT02288962     History of Changes
Other Study ID Numbers: 2012/677
2012-001338-32 ( EudraCT Number )
First Posted: November 13, 2014    Key Record Dates
Last Update Posted: December 27, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by St. Olavs Hospital:
dopamine agonists
Additional relevant MeSH terms:
Layout table for MeSH terms
Pituitary Neoplasms
Pituitary Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Hypothalamic Neoplasms
Supratentorial Neoplasms
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Dopamine Agonists
Cardiotonic Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents